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Multiple sclerosis (MS) is a progressive, autoimmune CD4+ T cell - mediated, inflammatory, 
demyelinating disease of central nervous system (CNS). Long-term MS therapy increases risk of 
opportunistic viral infections due to non-specific immune down-regulation. The important study from 
Spencer at al. revealed distinct changes within lymphocyte and leukocyte subsets in MS patients treated 
with dimethyl fumarate (DMF). [1] 
 
An overall reduction in immune cell counts and pronounced down-regulation of CD8+ T cells weaken 
innate immune responses to viruses in DMF treated MS patients. Viral infection can trigger autoimmune 
responses primary to development or progression of MS. Migration of chemokine receptor expressing 
activated autoimmune cells can be potentially controlled by viral chemokines. Crystallography data 
revealed interaction between viral vMIP-II and CXCR4. [2] CXCR4 and its endogenous ligand chemokine 
CXCL12 are implicated in MS. A CD4+ T cell specific chemotactic factor, cytokine IL-16, by binding to CD4 
co-receptor induces receptor desensitization of CXCR4 independent of p56lck enzymatic activity. [3] 
Production of IL-16 corresponds to CD4+ T cell inflammation, demyelination, and axonal degeneration in 
MS lesions. [4] Multifaceted properties of IL-16 include regulation of autoimmune and viral responses. 
[5] I propose use of IL-16 in combination MS therapy to avert complications of immune suppression. 
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